To be young, Black, and living with breast cancer: a systematic review of health-related quality of life in young Black breast cancer survivors Cleo A. SamuelLaura C. PinheiroStephanie B. Wheeler Review 06 September 2016 Pages: 1 - 15
The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis Michael J. RaphaelJames J. BiagiWilliam J. Mackillop Review 08 September 2016 Pages: 17 - 28
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer Julie O’NealAmy ClemBrian F. Clem Preclinical study 09 September 2016 Pages: 29 - 40
Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy John D. HainsworthPatrick B. MurphyDenise A. Yardley Clinical Trial 08 September 2016 Pages: 41 - 49
ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment C. C. O’SullivanM. LindenbergS. E. Bates Clinical Trial 12 September 2016 Pages: 51 - 59
Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group Shigeru TsuyukiNoriko SendaTakashi Inamoto Clinical Trial 12 September 2016 Pages: 61 - 67
Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer Juan Miguel CejalvoJ. Alejandro Pérez-FidalgoAna Lluch Clinical trial 14 September 2016 Pages: 69 - 77
Initial experience of the BREAST-Q breast-conserving therapy module Rachel L. O’ConnellRosa DiMiccoJennifer E. Rusby Clinical trial 16 September 2016 Pages: 79 - 89
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer Stephen JohnstonMark BasikMassimo Cristofanilli Clinical Trial 21 September 2016 Pages: 91 - 99
Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy Miho KonoTakeo FujiiNaoto T. Ueno Clinical trial 23 September 2016 Pages: 101 - 109
Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States Mark SiscoAlexandra M. KyrillosKatharine A. Yao Epidemiology 12 September 2016 Pages: 111 - 120
Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2 Irene CatucciSilvia CasadeiSusan L. Neuhausen Epidemiology 13 September 2016 Pages: 121 - 129
Long-term outcome in young women with breast cancer: a population-based study Hanna FredholmKristina MagnussonIrma Fredriksson Epidemiology Open access 13 September 2016 Pages: 131 - 143
Ten-year survival in women with primary stage IV breast cancer Lee Guek EngShaheenah DawoodRebecca Dent Epidemiology 14 September 2016 Pages: 145 - 152
Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient Thomas M. ChurillaBrian L. EglestonRichard J. Bleicher Epidemiology 17 September 2016 Pages: 153 - 162
Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry Akemi KataokaTakayuki IwamotoYutaka Tokuda Epidemiology Open access 19 September 2016 Pages: 163 - 172
Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour Ee Ming WongJiHoon E. JooMelissa C. Southey Brief Report 07 September 2016 Pages: 173 - 180
EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations Anna Sara NavazioPiera RizzoloLaura Ottini Brief Report 15 September 2016 Pages: 181 - 186
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States Vakaramoko DiabyGeorges AdunlinAlberto J. Montero Brief Report 21 September 2016 Pages: 187 - 196